Clinical Trials Logo

Filter by:
NCT ID: NCT06196775 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of cadonilimab combined with AK112 as second-line therapy in patients with advanced hepatocellular carcinoma.

NCT ID: NCT06196736 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Start date: December 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.

NCT ID: NCT06195670 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Start date: January 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with capecitabine in patients unfit for intensive therapy.

NCT ID: NCT06195267 Not yet recruiting - Aortic Dissection Clinical Trials

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Sivelestat) VI

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

NCT ID: NCT06192238 Not yet recruiting - Hyperaldosteronism Clinical Trials

China National Study of Adrenal Venous Sampling

CNAVS
Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

This multicenter study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of adrenal venous sampling (AVS) via antecubital and femoral approach for patients with primary aldosteronism. The consistency of AVS with pathological results and clinical outcomes, the factors affecting the success of AVS, and the optimal population for AVS will be aslo analyzed in this study.

NCT ID: NCT06191328 Not yet recruiting - Diabetes Clinical Trials

A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

Start date: January 31, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about inour study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration. The main question[s] it aims to answer are: - Quantitative lipidomics information enables in-depth analysis of lipids and can reveal Chiglitazar Sodium-specific lipid metabolic patterns, thereby strengthening lipidomics as a promising tool for exploring the molecular mechanisms of T2DM. - It can also be applied to other T2DM lipidomics studies to better understand lipid metabolism patterns and integration with other omics measures.

NCT ID: NCT06190275 Not yet recruiting - HNSCC Clinical Trials

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head neck squamous carcinoma (HNSCC) subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.

NCT ID: NCT06189495 Not yet recruiting - Clinical trials for Systemic Sclerosis Associated Interstitial Lung Disease

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Start date: December 30, 2023
Phase: Phase 2
Study type: Interventional

This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)

NCT ID: NCT06187896 Not yet recruiting - Hypoxia Clinical Trials

The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients

RP
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. In sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. The present study is a single-center, randomized, single-blind, controlled clinical trial. Overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with ASA grade I or II, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. Sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of severe hypoxia during surgery between the two groups of patients.

NCT ID: NCT06187142 Not yet recruiting - Smoking Cessation Clinical Trials

Mobile Phone-Based Smoking-Cessation Intervention for Chronic Patients

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The study aims to facilitate mobile phone-based cessation support for chronic patients using a sequential multiple assignment randomized trial (SMART) , and combines different effective treatments to enhance engagement and determine the most effective adaptive interventions.